Patents by Inventor Robert Slater

Robert Slater has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions having .beta.-adrenoceptor antagonist activity employing pyridazinone derivatives
    Patent number: 4678786
    Abstract: This invention relates to (isopropyl and tertiary butyl-amino-2-hydroxypropoxy)phenyl-3[2H]-pyridazinones which have .beta.-adrenoceptor antagonist activity.
    Type: Grant
    Filed: August 13, 1986
    Date of Patent: July 7, 1987
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Anthony M. Roe, William J. Coates, Robert A. Slater, Stephen P. Breukelman, George D. Meakins
  • Heterocyclic compounds having inotropic activity
    Patent number: 4657906
    Abstract: This invention relates to 5-(phenyl)-2(1H)-pyrazinones substituted in the 4-position of the phenyl ring by an amino or acylamino group. These compounds has inotropic activity. One specific compound is 5-(4-acetamidophenyl)-2(1H)-pyrazinone.
    Type: Grant
    Filed: September 19, 1985
    Date of Patent: April 14, 1987
    Assignee: Smith Kline & French Laboratories Ltd.
    Inventors: John C. Emmett, Robert A. Slater, Brian H. Warrington
  • 6-(cyanoguanidinophenyl)pyridazinones as cardiac stimulants
    Patent number: 4654342
    Abstract: This invention relates to cyanoguanidine derivatives that have utility in the treatment of congestive heart failure. A specific compound of this invention is 6-[4-(N.sup.3 -methyl-N.sup.2 -cyanoguanidino)phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone.
    Type: Grant
    Filed: January 14, 1985
    Date of Patent: March 31, 1987
    Assignee: Smith Kline & French Laboratories Ltd.
    Inventor: Robert A. Slater
  • Vasodilators and .beta.-adrenoceptor antagonists
    Patent number: 4652563
    Abstract: This invention relates to dihydropyridazinone compounds having a cyclopropylmethoxyethyl group in the 6-substituent. These compounds are vasodilators and .beta.-adrenoceptor antagonists. A particular compound of the invention is 6-[4-[3-[2-hydroxy-3-[4-(2-(cyclopropylmethoxy) ethyl)phenoxy]propylamino]propionamido]phenyl]-5-methyl-4,5-dihydro-3 (2H)-pyridazinone.
    Type: Grant
    Filed: May 16, 1985
    Date of Patent: March 24, 1987
    Assignee: Smith Kline & French Laboratories Ltd.
    Inventor: Robert A. Slater
  • 5-(4-substituted)phenyl-2-pyrazinones
    Patent number: 4632924
    Abstract: This invention relates to 5-(4-substituted)phenylpyrazinone compounds which have positive inotropic and vasodilator activity. One such compound is 5-(4-carboxamidophenyl)pyrazin-2(1H)-one.
    Type: Grant
    Filed: November 30, 1984
    Date of Patent: December 30, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: John C. Emmett, Robert A. Slater
  • 5-(4-Amino or acylaminophenyl)-2(1H)-pyrazinones having inotropic activity
    Patent number: 4556711
    Abstract: This invention relates to 5-(phenyl)-2(1H)-pyrazinones substituted in the 4-position of the phenyl ring by an amino or acylamino group. These compounds have inotropic activity. One specific compound is 5-(4-acetamidophenyl)-2(1H)-pyrazinone.
    Type: Grant
    Filed: June 2, 1983
    Date of Patent: December 3, 1985
    Assignee: Smith Kline & French Laboratories Ltd.
    Inventors: John C. Emmett, Robert A. Slater, Brian H. Warrington